We’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform?
No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Melanoma Drug Called a “Breakthrough” After Study
Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
New Software Brings Scientists Together
Imagine thousands of scientists across the globe collaborating to find a cure for cancer, or create a new malaria vaccine.
